BPC-157 had a big year in the headlines. It was pulled from an FDA safety list in the spring, and in July an FDA advisory panel narrowly voted to let compounding pharmacies make it. Many people took that to mean “BPC-157 is approved now.” It isn’t. This guide walks through exactly what happened, what each step means, and where things stand as of October 2026.
Key takeaways
- BPC-157 is not FDA-approved as a drug for any condition, and no company has completed the large human trials approval requires.
- On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend adding BPC-157 to the list of substances compounding pharmacies may use.
- That vote is advice, not a rule. The FDA must still decide, then go through formal rulemaking with public comment.
- BPC-157 remains banned in sport by WADA.
What BPC-157 is
BPC-157 (“body protection compound 157”) is a 15-amino-acid peptide derived from a protein found in stomach juice. It has been studied for decades in animals, mainly rats, for healing of tendons, ligaments, muscle, the gut lining and blood vessels. Human data are very limited: a few small pilot studies and case reports, and no large randomized controlled trials. That evidence gap is the core reason it isn’t an approved drug. For a comparison with its frequent partner, see BPC-157 vs TB-500.
Three different things people mean by “FDA approved”
| Pathway | What it means | BPC-157 status |
|---|---|---|
| FDA drug approval | A company proves safety and effectiveness in clinical trials. The drug gets a label and can be marketed for specific uses. | Not approved |
| 503A bulks list | A list of ingredients that licensed compounding pharmacies may use to make individual prescriptions, even without an approved drug version. | Recommended by an advisory panel in July 2026. Not yet added. |
| Category 2 (“significant safety risks”) | An FDA holding list for nominated ingredients the agency flagged as risky, which effectively stopped compounding. | Listed in 2023, removed April 2026 |
The timeline
- 2022: WADA names BPC-157 on its prohibited list as an unapproved substance, banned in and out of competition.
- September 2023: The FDA places BPC-157 and other peptides in Category 2, citing safety concerns such as possible immune reactions and impurities, and a lack of human safety data. Compounding pharmacies largely stop making it.
- February 27, 2026: HHS Secretary Robert F. Kennedy Jr. says many Category 2 peptides will be reconsidered.
- April 15, 2026: BPC-157 is one of 12 peptides removed from Category 2 after their nominations are withdrawn. Removal does not move them onto the approved compounding list.
- July 23, 2026: The Pharmacy Compounding Advisory Committee votes 8 to 6 (1 abstaining) to recommend BPC-157 for the 503A bulks list. The same day it backs KPV and TB-500 by the same margin and MOTS-c 7 to 5. The next day it backs Epitalon and Semax and rejects DSIP. FDA staff scientists had recommended against including the peptides reviewed.
- After the vote: No final rule has been reported as of this writing. Legal analysts note there is no fixed deadline. Past additions to the list have taken a year or more from proposed rule to final rule.
What happens next
For BPC-157 to be legally compounded under section 503A, the FDA would need to:
- Decide whether to accept the committee’s advice. It usually does, but not always.
- Publish a proposed rule and open a public comment period.
- Review comments and publish a final rule adding BPC-157 to the list.
Until that happens, compounding pharmacy law experts have cautioned that the vote is not permission to start compounding. Even if BPC-157 is added, it would only be available by prescription from a licensed pharmacy for an individual patient. It would still not be an FDA-approved drug, would not carry an FDA-reviewed label, and could not be sold as a dietary supplement.
What about “research use only” BPC-157 sold online?
Most BPC-157 sold today comes from websites labeled “for research use only, not for human consumption.” Those products are outside the FDA’s drug-quality system. Independent testing has repeatedly found products with the wrong amount, impurities or contamination. The FDA has sent warning letters to sellers marketing them for human use. If you see BPC-157 for sale, read what research use only actually means, how to read a certificate of analysis, and our list of vendor red flags.
Is BPC-157 legal?
In the US it isn’t a controlled substance, so possessing it isn’t a crime in the way controlled drugs are. Selling it for human use as an unapproved drug is not legal, and that’s the line regulators enforce. For athletes, it’s prohibited at all times under WADA rules, and tested athletes have been sanctioned. See peptides and drug testing.
Bottom line
The 2026 events moved BPC-157 closer to legal access through compounding pharmacies, but the process isn’t finished, and none of it amounts to FDA approval. Its safety and effectiveness in people remain unproven. Check the FDA’s compounding pages for the latest status before relying on any claim about legality.
Frequently asked questions
Is BPC-157 FDA approved in 2026?
No. BPC-157 is not an FDA-approved drug. In July 2026 an FDA advisory committee recommended adding it to the 503A bulks list for compounding, but that is a separate step from approval and was not final as of October 2026.
What was the FDA vote on BPC-157?
On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend adding BPC-157 to the 503A bulks list.
Can compounding pharmacies make BPC-157 now?
Legal analysts advise that the advisory vote alone does not authorize compounding. The FDA must complete rulemaking to add BPC-157 to the 503A bulks list.
Why was BPC-157 in Category 2?
In 2023 the FDA flagged it for potential safety risks, including immune reactions and impurities, and a lack of human safety data. It was removed from Category 2 in April 2026 after its nomination was withdrawn.
Is BPC-157 banned in sports?
Yes. WADA prohibits BPC-157 at all times as a non-approved substance.
Sources
- McDermott Will and Schulte, PCAC backs majority of peptides in two-day public meeting, July 2026
- Buchanan Ingersoll and Rooney, FDA advisory committee voted yes on six peptides. Now what?, August 2026
- ABC News, FDA advisers narrowly vote to add 6 peptides to a drug compounding list, July 24, 2026
- STAT News, FDA advisory panel narrowly votes to allow compounding of unapproved peptides, July 23, 2026
- World Anti-Doping Agency Prohibited List, section S0
Medical disclaimer: Pep Guide is for educational purposes only. It is not medical advice, diagnosis or treatment. Research changes over time. Talk to a licensed healthcare provider before starting, stopping or changing any medication or compound.